NABI: Summary for Nabi Biopharmaceuticals - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:35am EST - Canadian Markets open in 3 hours and 55 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Nabi Biopharmaceuticals (NABI)

On Feb 9: 4.93 USD 0.00 (0.00%)

MORE ON NABI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Nabi Biopharmaceuticals (NGM:NABI) Delayed quote data

Last Trade:	4.93 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	4.93
Open:	N/A
Bid:	4.00 x 200
Ask:	7.25 x 800
1y Target Est:	9.25

Day's Range:	N/A - N/A
52wk Range:	2.15 - 5.60
Volume:	0
Avg Vol (3m):	400,592
Market Cap:	250.25M
P/E (ttm):	N/A
EPS (ttm):	-0.33
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add NABI to Portfolio

Download Data

HEADLINES

•	Coverage initiated on NABI Biopharma by C.K. Cooper
	Briefing.com (Wed, Jan 6)

•	4-Star Stocks on the Upswing
	at Motley Fool (Tue, Dec 15)

•	NABI BIOPHARMACEUTICALS Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Wed, Nov 25)

•	This Partnership Is Smoking!
	at Motley Fool (Tue, Nov 17)

•	Nabi Biopharmaceuticals Conference Call to discuss announcement of the exclusive worldwide option and licensing agreement for NicVAX(R) scheduled for 11:00 am ET today
	CCBN (Tue, Nov 17)

•	Glaxo and Nabi Team Up for Nicotine Vaccine
	at Minyanville.com (Tue, Nov 17)

•	[$$] Sonic Solutions, Nabi and Bristow Advance
	at The Wall Street Journal Online (Mon, Nov 16)

•	NABI BIOPHARMACEUTICALS Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi
	EDGAR Online (Mon, Nov 16)

•	Nabi soars on Glaxo deal for smoking vaccine
	at bizjournals.com (Mon, Nov 16)

•	Sprint, CombinatoRx: Early Volume Plays
	at TheStreet.com (Mon, Nov 16)

More Headlines for NABI...

ANALYST

EPS Est (next year) (Dec-09) :	-0.50
EPS Est (in 2 years) (Dec-10) :	-0.18
Avg Rec (current)*:	1.5
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•